Detection of Polyfunctional Mycobacterium tuberculosis Specific T Cells and Association with Viral Load in HIV-1 Infected Persons
|
|
- Christopher Parsons
- 6 years ago
- Views:
Transcription
1 MAJOR ARTICLE Detection of Polyfunctional Mycobacterium tuberculosis Specific T Cells and Association with Viral Load in HIV-1 Infected Persons Cheryl L. Day, 1,3,4,a Nompumelelo Mkhwanazi, 1 Sharon Reddy, 1 Zenele Mncube, 1 Mary van der Stok, 1 Paul Klenerman, 2 and Bruce D. Walker 1,3,4,5 1 HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu Natal, Durban, South Africa; 2 Nuffield Department of Medicine, The Peter Medawar Building for Pathogen Research, Oxford University, Oxford, United Kingdom; 3 Partners AIDS Research Center, Massachusetts General Hospital, and 4 Division of AIDS, Harvard Medical School, Boston, Massachusetts; and 5 Howard Hughes Medical Institute, Chevy Chase, Maryland (See the editorial commentary by Lalvani and Millington, on pages ) Background. The human immunodeficiency virus type 1 (HIV-1) epidemic is associated with a significant increase in the incidence of tuberculosis (TB); however, little is known about the quality of Mycobacterium tuberculosis (MTB) specific cellular immune responses in coinfected individuals. Methods. A total of 137 HIV-1 positive individuals in Durban, South Africa, were screened with the use of overlapping peptides spanning Ag85A, culture filtrate protein 10 (CFP-10), early secretory antigen target 6 (ESAT-6), and TB10.4, in an interferon (IFN) enzyme-linked immunospot (ELISPOT) assay. Intracellular cytokine staining for MTB-specific production of IFN-, tumor necrosis factor (TNF), and interleukin (IL) 2 was performed, as was ex vivo phenotyping of memory markers on MTB-specific T cells. Results. A total of 41% of subjects responded to ESAT-6 and/or CFP-10, indicating the presence of latent MTB infection. The proportion of MTB-specific IFN- /TNF- CD4 cells was significantly higher than the proportion of IFN- /IL-2 CD4 cells (P.0220), and the proportion of MTB-specific IL-2 secreting CD4 cells was inversely correlated with the HIV-1 load (P.0098). MTB-specific CD8 T cells were predominately IFN- /TNF- /IL-2. Ex vivo memory phenotyping of MTB-specific CD4 and CD8 T cells indicated an early to intermediate differentiated phenotype for the population of effector memory cells. Conclusions. Polyfunctional MTB-specific CD4 and CD8 T cell responses are maintained in the peripheral blood of HIV-1 positive individuals, in the absence of active disease, and the functional capacity of these responses is affected by HIV-1 disease status. Approximately 90% of HIV-1 negative individuals infected with Mycobacterium tuberculosis (MTB) do not Received 24 September 2007; accepted 29 October 2007; electronically published 4 March Potential conflicts of interest: none reported. Financial support: National Institutes of Health (grant R01 AI067073); Mark and Lisa Schwartz Foundation. Presented in part: 3rd South African AIDS Conference, Durban, South Africa, June 2007 (poster A61). a Present affiliation: South African Tuberculosis Vaccine Initiative, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. Reprints or correspondence: Dr. Cheryl L. Day, South African Tuberculosis Vaccine Initiative, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, S1.02 Wernher and Beit Bldg., Anzio Rd., Observatory 7925, Cape Town, South Africa (cheryl.day@uct.ac.za). The Journal of Infectious Diseases 2008; 197: by the Infectious Diseases Society of America. All rights reserved /2008/ $15.00 DOI: / develop active disease after initial MTB infection; this observation provides compelling evidence that the host immune response is usually successful in containing the infection [1, 2]. Coinfection with HIV-1, which impairs cellular immune responses, greatly increases the risk of development of active tuberculosis (TB) [3, 4], and the HIV-1 epidemic has contributed significantly to the rapid spread of TB, as well as to subsequent increases in the number of cases of active disease in such areas as sub-saharan Africa [5]. Previous studies in interferon (IFN) deficient mice and in humans with IFN- receptor abnormalities have indicated an essential role of IFN- producing T cells in the containment of MTB infection [6 9]. IFN- secreting T cells specific for multiple immunogenic antigens of MTB have been identified, including the Ag85 complex, culture filtrate protein 10 (CFP-10), 990 JID 2008:197 (1 April) Day et al.
2 early secretory antigenic target 6 (ESAT-6), heat shock protein 65, and TB10.4 [10 16]. Recently, tests have been developed for immunodiagnosis of MTB infection on the basis of the presence of IFN- secreting cells in response to the following antigens in the region of difference 1 (RD1): ESAT-6 and CFP-10; these tests have been shown to be more specific and sensitive than tuberculin skin tests [17]. The RD1 antigens have been deleted from all Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccines [18] and are, therefore, useful in differentiating individuals who have been exposed to MTB within a BCG-vaccinated population. Although the majority of studies of the performance of IFN- release assays for the detection of MTB infection have been performed in HIV-1 negative cohorts, the performance of these assays has not been found to be significantly affected by HIV-1 infection in studies involving HIV-1 positive subjects [19 24]. Despite the high prevalence of coinfection with HIV-1 and MTB, very little information is currently known about the functional capacity of MTB-specific cellular immune responses in HIV-1 positive individuals. A high sensitivity for the detection of MTB infection has been noted with the use of an RD1-based IFN- enzyme-linked immunospot (ELISPOT) assay in the screening of HIV-1 positive patients with TB, including both adults and children [19, 21, 25]. However, the degree to which HIV-1 coinfection influences the magnitude of responding MTB-specific T cells in patients with TB varies in different study cohorts [19, 26, 27]. Moreover, detailed analyses of the effector functions of MTB-specific T cell responses in HIV-1 positive individuals with latent and active TB, as well as the extent to which HIV-1 disease progression influences the functional capacity of these responses, have not been well described. In the present study, we characterized the MTB-specific T cell response in HIV-1 positive individuals with latent TB from KwaZulu Natal, South Africa, where 80% of active TB cases are associated with HIV-1 infection [28]. Our aims were to determine the magnitude and breadth of responses to mycobacterial antigens, to determine the relationship between MTB-specific T cell responses and parameters of HIV-1 disease progression, and to assess the ex vivo phenotype of MTB-specific T cells and their capacity to secrete multiple cytokines in individuals with chronic HIV-1 infection. MATERIALS AND METHODS Subjects. One hundred thirty-seven subjects were recruited from the Sinikithemba Care Center at McCord Hospital in Durban, South Africa. All subjects were HIV-1 positive and antiretroviral therapy naive, and they had no previous history of TB symptoms, diagnosis, or treatment, as well as no current symptoms of active TB. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples by means of density centrifugation with ficoll-hypaque (Sigma). The HIV-1 load was measured using the Roche Amplicor assay (version 1.5). The median viral load of the cohort was 20,500 HIV-1 RNA copies/ml of plasma, and the median absolute CD4 cell count was 359 cells/ L of whole blood. Five HIV-1 negative subjects from the United States who were not vaccinated with BCG and who had no previous history of TB were included as negative controls. All study participants provided written, informed consent for the study, which was approved by institutional review boards. Synthetic peptides. Peptides (16- to 18-mers overlapping by 10 aa) corresponding to the sequence of the MTB antigens Ag85A, CFP-10, ESAT-6, and TB10.4 were synthesized on an automated peptide synthesizer. For initial screening purposes, peptides were arranged into pools of 9 peptides each in a matrix fashion, such that each peptide was uniquely represented in 2 pools [29]. IFN- ELISPOT assays. Ninety-six well polyvinylidene plates (Millipore) were precoated with 0.5 g/ml anti human IFN- monoclonal antibody (1-D1K; Mabtech). A total of 100,000 freshly isolated PBMCs were added per well in a volume of 100 L of R10 medium (RPMI 1640 supplemented with 10% fetal calf serum, 10 mmol/l HEPES buffer, 2 mmol/l L-glutamine, and 50 U/mL penicillin-streptomycin). Peptides were added at a final concentration of 2 g/ml. Negative controls consisted of wells containing PBMCs incubated with medium alone. Positive controls consisted of wells containing PBMCs and 12.5 g/ml phytohemagglutinin (PHA; Murex Biotech). Plates were incubated overnight at 37 C in a 5% CO 2 incubator and were washed the next morning; 0.5 g/ml biotinylated anti IFN- antibody (7-B6-1; Mabtech) was then added for 1.5 h, and the plates were washed and incubated with streptavidin-alkaline phosphatase (Mabtech) for 45 min. The plates were developed by the addition of the alkaline phosphatase color reagents 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium chloride in Tris buffer (ph 9.5). The reaction was stopped by washing with tap water after the appearance of intense blue spots in the positive control wells. Spots were counted on an ELISPOT reader (AID), and responses were considered to be positive if the number of spots per well minus the background value was 50 spot-forming cells (SFCs)/10 6 PBMCs (i.e., if the value was greater than the mean value plus 3 times greater than the standard deviation of the responses in the negative control subjects). Intracellular cytokine staining and immunophenotyping. A total of PBMCs were incubated with 1 g of peptide in 1 ml of R10 medium overnight (12 14 h) at 37 C in a 5% CO 2 incubator. After the first hour of incubation, 10 g of brefeldin A (Sigma) was added. The cells were washed and stained with the following surface antibodies at room temperature for 15 min: peridinin-chlorophyll-protein complex (PerCP) conjugated anti-cd4, allophycocyanin (APC) conjugated anti-cd8, fluorescein isothiocyanate (FITC) conjugated anti-cd27, APCconjugated anti-cd28, APC-conjugated anti-cd45ra, FITC- MTB-Specific T Cells in HIV-1 Infection JID 2008:197 (1 April) 991
3 conjugated anti-ccr7 (R&D Systems), and APC-conjugated CD62L. The cells were washed, fixed, and permeabilized (Caltag reagents A and B; Caltag Laboratories). The following intracellular antibodies were then added: FITC-conjugated anti-ifn-, phycoerythrin (PE) conjugated TNF-, PE-conjugated IL-2, and APC-conjugated Granzyme B (GrB; Caltag Laboratories). All antibodies were from Becton Dickinson, unless otherwise noted. The cells were incubated for 15 min and then were washed and acquired on a FACSCalibur flow cytometer with the use of CellQuest software (Becton Dickinson). Negative controls consisting of PBMCs incubated with medium alone were included in each assay. Responses 0.03% above the background value were considered to be positive. For phenotypic analysis of CD4 cells, peptide-stimulated cells were gated on CD4 TNF- cells and analyzed for expression of CD27, CD28, CD45RA, CCR7, and CD62L. For phenotypic analysis of CD8 cells, peptidestimulated cells were gated on CD8 TNF- cells and analyzed for expression of CD27, CD28, CD45RA, CCR7, and GrB. Statistical analysis. The Mann-Whitney U test and Spearman rank correlation were performed using GraphPad Prism software (version 4.0; GraphPad Prism). P.05 was considered to be statistically significant. RESULTS Identification of MTB-specific T cell responses in HIV-1 positive individuals with latent MTB infection. To characterize the MTB-specific cellular immune response in HIV-1 positive individuals in an area of endemicity for TB who are at high risk for reactivation and development of active disease, we screened a large cohort of individuals with chronic HIV-1 infection for the presence of IFN- producing T cells. Screening was performed using an ELISPOT assay for the detection of MTB RD1 antigens CFP-10 and ESAT-6, as well as the immunogenic secreted antigens Ag85A [11] and TB10.4 [30, 31]. Fifty-six (41%) of 137 subjects had positive responses to ESAT-6 and/or CFP-10, according to the ELISPOT assay (data not shown), and they were thus identified as subjects with latent MTB infection. No significant differences in either absolute CD4 cell count or viral load were observed between individuals with detectable and undetectable MTB-specific responses in the IFN- ELISPOT assay (data not shown). Forty-one of the 56 subjects with positive responses in the initial screening performed with the peptide pools had sufficient numbers of cells available with which to perform a second ELISPOT assay the next day to confirm the individual peptides eliciting the positive response. All of the subjects responded to at least one peptide in either CFP-10 and/or ESAT-6, thus confirming all initial positive responses at an individual peptide level; 44% of subjects responded to peptides from both CFP-10 and ESAT-6, whereas 34% responded to ESAT-6 only and 22% responded to CFP-10 only (figure 1A). All subjects responding to Figure 1. Magnitude and breadth of Mycobacterium tuberculosis (MTB) specific T cell responses in HIV-positive individuals with latent infection. 18-mer overlapping peptides spanning the Ag85A, culture filtrate protein 10 (CFP-10), early secretory antigen target 6 (ESAT-6), and TB10.4 proteins were arranged in pools of 9 peptides each in a matrix fashion such that each peptide was represented in 2 pools. Freshly isolated peripheral blood mononuclear cells (PBMCs) were screened for positive responses to the peptide pools in an interferon (IFN)- enzymelinked immunospot (ELISPOT) assay; responses to individual peptides were reconfirmed in a second ELISPOT assay. Positive responses to individual 18-mer peptides from the confirmation assay are shown; for 41 individuals, a second confirmatory ELISPOT assay with individual peptides was performed. A, Frequency (percentage) of subjects with a positive IFN- ELISPOT assay response who demonstrated a response to each of the 4 antigens tested. Individuals were considered to be responders if they targeted at least one peptide within the antigen indicated. B, Magnitude of T cell responses to individual peptides (Ag85A, CFP-10, ESAT-6, and TB10.4 peptides) in an IFN- ELISPOT assay. Horizontal lines denote the median number of spot-forming cells (SFCs) per million PBMCs. C, No. of peptides targeted per individual within each antigen and across all antigens tested. Horizontal lines denote median values. 992 JID 2008:197 (1 April) Day et al.
4 peptides in Ag85A or TB10.4 also responded to at least one other peptide in ESAT-6 and/or CFP-10 (data not shown). The magnitudes of the positive responses to individual peptides within the 4 antigens tested ranged from 50 to 2000 SFCs/ million PBMCs. The median magnitude was highest for TB10.4- specific cells, although this finding was not significantly different from responses directed against CFP-10 (median magnitude, 219 SFCs/million PBMCs) or ESAT-6 (median magnitude, 171 SFCs/million PBMCs) (figure 1B). The number of epitopes targeted (per individual) within each antigen tested ranged from 1 to 6 (figure 1C). Overall, summing up the responses to epitopes in all 4 antigens tested, the breadth of responses ranged from 1 to 16 epitopes simultaneously targeted in a single subject, with a median of 2 epitopes targeted (figure 1C). Identification of immunodominant epitopes in CFP-10 and ESAT-6. We next analyzed the frequency of recognition of individual overlapping peptides in CFP-10 and ESAT-6, to further map immunodominant epitopes targeted in this population. Ten of 12 overlapping peptides for CFP-10 were recognized by 1 subject, with 2 dominant epitopes (CFP and CFP ) each targeted by 37% of subjects (figure 2A). Eleven of 12 ESAT-6 peptides were recognized by 1 subject. The most frequently targeted peptides (ESAT and ESAT ) were each recognized by 27% of subjects. Peptides overlapping with the sequences of the 4 most dominant peptides identified in the present study have previously been reported to be frequently recognized by HIV-1 negative subjects in Indian, European, Cambodian, and Middle Eastern cohorts with both latent and active TB [14, 21, 32 35]. Furthermore, ESAT and CFP have been described to be immunodominant in HIV-1 positive patients with TB and asymptomatic adults in Zambia [19]. Taken together, these data indicate that the pattern of epitope recognition in these antigens may be similar among ethnically diverse populations of HIV-1 positive and HIV-1 negative individuals. Analysis of cytokine production by MTB-specific CD4 and CD8 T cells at the single-cell level. The aforementioned experiments using the IFN- ELISPOT assay were designed to identify HIV-1 positive subjects with evidence of latent TB. Because IFN- is but one of the cytokines produced by antigenspecific T cells, we next determined the ability of MTB-specific T cells in these subjects to secrete additional cytokines by use of an intracellular cytokine staining assay to detect IFN-, TNF-, and IL-2 after short-term stimulation with individual ESAT-6 or CFP-10 peptides. Representative data are shown in figure 3A, and composite data (n 40) are shown in figure 3B. There was no statistical difference in the median frequency of IFN-, TNF-, and IL-2 secreting CD4 cells (0.065%, 0.095%, and 0.075% of CD4 cells, respectively). The majority of MTB-specific T cell responses identified in this cohort were CD4 mediated; however, we were able to identify subjects with detectable MTB-specific CD8 T cell responses. Figure 2. Frequency of recognition of individual culture filtrate protein 10 (CFP-10) and early secretory antigen target 6 (ESAT-6) peptides. The percentage of individuals responding to each individual overlapping 18-mer peptide spanning the length of the secreted antigens culture filtrate protein 10 (CFP-10) (A) or ESAT-6 (B) in an ex vivo interferon- enzyme-linked immunospot (ELISPOT) assay is shown. Subjects were screened for responses to overlapping 18-mer CFP-10 and ESAT-6 peptides, as described in the figure 1 legend. Forty-one subjects had positive ELISPOT assay responses to either CFP-10 and/or ESAT-6. Representative data are shown in figure 3C, with composite data of CD8 responses in 14 subjects shown in figure 3D. The median frequency of MTB-specific cells secreting IFN- and TNF- to an individual ESAT-6 or CFP-10 peptide was 0.060% and 0.055%, respectively, of CD8 cells. The frequency of IFN- and TNF- secreting CD8 cells was significantly higher than the median frequency of MTB-specific IL-2 secreting CD8 cells (P.0001 and P.0009, respectively) (figure 3D). Assessment of production of multiple cytokines by antigenspecific T cells is thought to be an indication of functionality, MTB-Specific T Cells in HIV-1 Infection JID 2008:197 (1 April) 993
5 Figure 3. Cytokine production by Mycobacterium tuberculosis (MTB) specific CD4 and CD8 T cells. A, Representative intracellular cytokine staining (ICS) data for a subject whose cells were stimulated with peptide culture filtrate protein 10 (CFP-10; in this case, CFP ) and stained intracellulary for interferon (IFN), tumor necrosis factor (TNF), and interleukin (IL) 2. The percentages in the upper right quadrant denote the percentage of CD4 cytokine-positive cells, with background cytokine production values subtracted. Top, no antigen stimulation; Bottom, peripheral blood mononuclear cells (PBMCs) stimulated for 12 h with CFP peptide. B, Composite data on IFN-, TNF-, and IL-2 production by CD4 T cells in response to individual TB peptides, as tested by ICS (n 40). For the ICS assay, each subject was tested with individual early secretory antigen testing 6 and CFP-10 peptides that elicited a positive response from that subject in the initial IFN- enzyme-linked immunospot (ELISPOT) screening assay. Horizontal bars denote the median percentage of CD4 cytokine-positive cells. C, Representative ICS data for a subject whose cells were stimulated with peptide CFP and stained intracellularly with IFN-, TNF-, and IL-2. The percentage in the upper right quadrant denotes the percentage of CD8 cytokine-positive cells, with background cytokine production values subtracted. Top, no antigen stimulation; Bottom, PBMCs stimulated for 12 h with CFP peptide. D, Summary data of IFN- (n 14), TNF- (n 12), and IL-2 (n 11) production by CD8 T cells in response to individual MTB peptides tested by ICS. Horizontal lines denote median percentages of CD8 cytokine-positive cells. with loss of cytokine production indicative of impairment of function [36]. To address whether there was evidence of impaired function of MTB-specific T cells in HIV-1 positive individuals, we assessed the frequency of MTB-specific CD4 and CD8 T cells that were able to secrete multiple cytokines simultaneously. Because only a 4-color flow cytometer was available on site in Durban, we performed costaining for IFN- /IL-2 and IFN- /TNF- separately. Representative data shown in figure 4A indicated that the majority ( 75%) of MTB-specific CD4 T cells are polyfunctional: IFN- /IL-2 and IFN- /TNF-. The proportion of INF- /TNF- cells was significantly greater than the proportion of IFN- /IL-2 cells (P.0220). Although there were virtually no IFN- /TNF- cells detectable, a small but significant proportion of MTB-specific CD4 cells that were IFN- /IL-2 was detected (P.0001). We similarly addressed the polyfunctional cytokine-secreting capacity of MTB-specific CD8 cells by costaining with IFN- / IL-2 and IFN- /TNF- (figure 4C), and we found a dominance of IFN- /IL-2 cells and IFN- /TNF- cells (figure 4D). The proportion of TB-specific IFN- /IL-2 CD8 cells was significantly lower than the proportion of IFN- /TNF- cells (P.0001) (figure 4D). Relationship between functionality of MTB-specific T cell responses and parameters of HIV-1 disease progression. To determine the impact of HIV-1 coinfection on the functionality of MTB-specific T cell responses, we next analyzed the relationship between the breadth and magnitude of MTB-specific T cell responses, as determined by the IFN- ELISPOT assay, in relation to HIV-1 disease progression, including absolute CD4 cell count and HIV-1 load, and we found no correlations (data not shown). However, analysis of the cytokine costaining data indicated an inverse correlation between the proportion of TBspecific IL-2 secreting (IFN- /IL-2 and IFN- /IL-2 ) CD4 cells and the viral load, and a corresponding positive correlation 994 JID 2008:197 (1 April) Day et al.
6 Figure 4. Polyfunctional cytokine analysis of Mycobacterium tuberculosis (MTB) specific CD4 and CD8 T cells. A, Representative intracellular cytokine staining (ICS) data from peripheral blood mononuclear cells (PBMCs) stimulated with culture filtrate protein 10 (CFP-10; in this case, CFP ) peptide and costained with interferon (IFN) /interleukin (IL) 2 and IFN- /tumor necrosis factor (TNF). Cells were gated on CD4 events, and the percentages denote the percentage of CD4 cytokine-positive cells in each quadrant. The background cytokine production value has been subtracted from the percentages shown in the lower 2 plots. B, Analysis of the proportion of MTB-specific CD4 cells that are IFN- /IL-2, IFN- /IL-2, IFN- /IL-2, IFN- /TNF-, IFN- /TNF-, and IFN- /TNF-. PBMCs were stimulated with peptide overnight and were costained with either IFN- and IL-2 or IFN- and TNF-, as indicated in panel A. The median value and interquartile range for each population are shown (40 subjects had IFN- /IL-2 costaining done, and 26 had IFN- /TNF- costaining done). Statistical comparisons were made using the Mann-Whitney test. C, Representative ICS data for MTB-specific CD8 cells stimulated with CFP peptide and costained with IFN- /IL-2 and IFN- /TNF-. Cells were gated on CD8 events, and the percentage of CD8 cytokine cells is shown in the quadrants; the background cytokine production value has been subtracted in the lower 2 plots. D, The proportion of MTB-specific CD8 cells that are IFN- /IL-2, IFN- /IL-2, IFN- /IL-2, IFN- /TNF-, IFN- /TNF-, and IFN- /TNF-. The median value and interquartile range are shown for each population (10 subjects had IFN- /IL-2 costaining done, and 9 had IFN- /TNF- costaining done). Statistical comparisons were made using the Mann-Whitney test. E, Inverse correlation between the proportion of MTB-specific IL-2 secreting CD4 cells and HIV-1 load (P.0098, by Spearman correlation; n 40). Results are presented as the percentage of IL-2 positive cells (IFN- /IL-2 and IFN- /IL-2 ) contributing to the total MTB-specific response to individual CFP-10 or early secretory antigen target 6 peptides.
7 Figure 5. Memory phenotypic analysis of Mycobacterium tuberculosis (MTB) specific CD4 and CD8 T cells. A, Representative MTB-specific CD4 memory phenotyping data for a subject with cells stimulated with peptide culture filtrate protein 10 (CFP-10; in this case, CFP ). Peripheral blood mononuclear cells (PBMCs) were gated on CD4 TNF- cells and analyzed for expression of memory markers CD27, CD28, CD45RA, CCR7, and CD62L, as indicated. The percentages in the flow plots denote the percentage of CD4 TNF- cells that express the markers indicated. B, Summary data of the memory phenotype of MTB-specific CD4 T cells. PBMCs were stimulated with individual peptides and gated on CD4 TNF- cells, as shown in panel A (n 14 subjects). Horizontal lines denote median expression of the indicated marker on MTB-specific CD4 T cells. C, Representative MTB-specific CD8 memory phenotyping data for a subject with cells stimulated with peptide CFP PBMCs were gated on CD8 TNF- cells and were analyzed for expression of the memory and effector markers CD27, CD28, CD45RA, CCR7, and Granzyme B (GrB; Caltag Laboratories), as indicated. The percentages in the quadrants denote the percentage of CD8 TNF- cells that express the markers indicated. D, Summary of phenotyping data of MTB-specific CD8 T cells (n 6 subjects). PBMCs were stimulated with individual MTB peptides and gated on CD8 TNF- cells, as indicated in panel C. Horizontal lines denote median expression of the indicated marker on MTB-specific CD8 T cells. between IFN- /IL-2 CD4 cells and the viral load (P.0098) (figure 4E). These data indicate that IL-2 secreting MTBspecific CD4 T cells are diminished or have impaired function under conditions of high levels of HIV-1 viremia. Phenotypic analysis of MTB-specific CD4 and CD8 T cells. Antigen-specific T cells can be classified into different populations of memory and effector cells on the basis of the expression of phenotypic markers associated with maturation status. To determine the phenotypic profile of MTB-specific CD4 T cells associated with latent TB, we used the intracellular cytokine staining assay to stimulate PBMCs with individual peptides, gating on CD4 TNF- cells and analyzing expression of the memory markers CD27, CD28, CCR7, CD45RA, and CD62L (figure 5A). MTB-specific CD4 T cells were found to be CCR7 lo CD45RA lo CD62L lo, indicating an effector memory phenotype (n 14) (figure 5B). The high level of expression of CD28 and the intermediate level of CD27 expression denote an early to intermediate differentiated phenotype. Phenotypic analysis of MTB-specific CD8 T cells was performed by stimulating PBMCs with individual peptides and gating on CD8 TNF- cells for analysis of CD27, CD28, CCR7, CD45RA, and GrB expression (figure 5C). MTB-specific CD8 T cells were found to be CCR7 lo CD45RA lo GrB hi, indicating an effector phenotype (n 6) (figure 5D). Similar to MTB-specific CD4 cells, MTB-specific CD8 cells demonstrated high levels of expression of CD28 and intermediate levels of expression of CD27, suggesting an early to intermediate differentiated phenotype. DISCUSSION This is the first detailed study to characterize MTB-specific CD4 and CD8 T cell responses at the single-cell level in HIV-1 positive adults with latent TB. We used an IFN- ELISPOT-based assay using overlapping peptides spanning the RD1 antigens ESAT-6 and CFP-10 to identify HIV-1 positive subjects with 996 JID 2008:197 (1 April) Day et al.
8 latent TB in KwaZulu Natal Province, South Africa, where extensively drug-resistant TB recently has been detected [28]. Our rate of detection of latent TB by use of this RD1-based IFN- ELISPOT assay in this cohort was 41%, a rate similar to that reported in a previous study of HIV-1 positive asymptomatic adults in Zambia, in which 9 (43%) of 21 subjects responded to RD1 peptides in an IFN- ELISPOT assay [19]. The frequency of latent TB in our study population in South Africa is likely to be even higher than that identified here, because some individuals, particularly those with extremely low CD4 cell counts ( 100 cells/ L), may have responses below the level of detection of the ELISPOT assay [20, 24], or they may respond to antigens other than CFP-10 or ESAT-6. Tests for the identification of individuals with latent TB may be useful in predicting who will develop active disease [37], although longitudinal studies are still required to determine the prognostic value of positive responses to CFP-10/ESAT-6 in the development active disease. Analysis of production of multiple cytokines by antigenspecific T cells is an important measurement of their functionality, and such production is thought to be associated with antigen load [38, 39]. Because of the limitations associated with the use of a 4-color flow cytometer in KwaZulu Natal, we costained cells with either IFN- and IL-2 or IFN- and TNF-, and, because a median of 75% of MTB-specific CD4 cells were IFN- /TNF- and IFN- /IL-2, we can infer that the majority of MTB-specific CD4 cells are polyfunctional and secrete all 3 cytokines simultaneously. However, we found a significantly higher proportion of MTB-specific CD4 cells that were IFN- / TNF-, compared with IFN- /IL-2, suggesting that IL-2 secretion capacity may be lost first (before the loss of TNF- or IFN- ). This finding is consistent with murine models of lymphocyte choriomeningitis virus that indicate a hierarchal loss of function of antigen-specific T cells under conditions of persistent antigen stimulation, with loss of IL-2 production preceded by loss of TNF- synthesis and then, finally, by loss of IFN- production [40]. Previous studies involving HIV-1 positive individuals have also indicated loss of IL-2 function by HIV-1 specific CD4 T cells in subjects with progressive disease [41]. The inverse correlation found between the proportion of MTB-specific IL-2 secreting CD4 cells and viral load suggests that MTB-specific CD4 T cells in HIV-1 positive subjects may gradually lose IL-2 secretion capacity as HIV-1 disease progresses. This finding has important implications for MTB pathogenesis, because these responses may already be impaired by the time of reactivation, thus potentially contributing to the rapid course of TB disease often seen in HIV-1 positive individuals. The time of MTB infection is not known in this cohort, and longitudinal studies would need to be performed to determine how the duration of MTB and HIV-1 coinfection affects the IL-2 secretion capacity of MTB-specific CD4 cells. It is important to note that there was no correlation between the total frequency of MTB-specific IFN-, IL-2, or TNF- CD4 cells and viral load or CD4 count, thus underscoring the need to analyze multiple cytokine functions simultaneously to determine the impact of HIV-1 infection on the functional capacity of MTB-specific T cells. A previous study indicated reduced frequencies of purified protein derivative specific IFN- /IL-2 CD4 T cells in BCGvaccinated HIV-positive subjects, compared with BCGvaccinated HIV-negative subjects [42]. In the present study, we were unable to recruit HIV-1 negative individuals with latent TB to directly compare the functional profile of MTB-specific T cell responses in HIV-1 positive and negative individuals and to determine the relative contributions of these 2 pathogens in the impairment of MTB-specific T cell function. However, a recent study assessing the capacity for IFN- and IL-2 secretion by MTB-specific T cells in HIV-1 negative subjects with active TB indicated codominance of IFN- /IL-2 and IFN- /IL-2 cells, followed by a shift to dominance of IFN- /IL-2 cells after treatment [39]. Taken together, these data imply that establishment of active disease may further impair MTB-specific T cell function, as evidenced by lack of IL-2 secretion capacity. Phenotypic analysis of antigen-specific T cells provides important information regarding effector function and maturation status, and it has been well described in human viral infections [43 47] but less so in such bacterial infections as MTB infection. We found the phenotype of MTB-specific CD4 and CD8 cells to be intermediate differentiated effector memory cells, consistent with findings of previous studies of chronically infected mice [48, 49]. Our phenotypic analysis of MTB-specific T cells provides new insights into the development of MTB-specific memory cells in humans. MTB-specific CD8 T cells displayed an unusual phenotype for antigen-specific CD8 T cells in that they exhibited high CD28 expression and intermediate CD27 expression, while they also maintained high GrB expression, which may represent a dysregulated phenotype associated with MTB infection. Antigen-specific CD8 T cells in viral infections are thought to start off as CD27 /CD28 (early differentiated phenotype) and then lose CD28 expression (CD27 /CD28 ; intermediate differentiated phenotype) before losing CD27 expression (CD27 /CD28 ; late differentiated phenotype) [44]. However, we found MTB-specific CD8 T cells to be high in CD28 expression and lower in CD27 expression, suggesting that they lose CD27 expression first (before they lose CD28 expression), consistent with the model that has been proposed for antigen-specific CD4 cell differentiation rather than antigenspecific CD8 T cells. There is no accurate test for antigen levels associated with MTB infection in humans, and it is not known whether there is some degree of bacterial replication ongoing in these HIV-1 positive subjects (despite the absence of symptoms of active TB) that may drive these cells to maintain an effector memory phenotype. Furthermore, we did not have access to chest radiographs of these subjects, and it is possible that a pro- MTB-Specific T Cells in HIV-1 Infection JID 2008:197 (1 April) 997
9 portion of these asymptomatic subjects had undiagnosed, subclinical, active TB. In conclusion, we found that polyfunctional MTB-specific CD4 and CD8 T cell responses with an effector memory phenotype are readily detectable in the absence of active TB disease in HIV-1 positive subjects. The proportion of IL-2 secreting MTB-specific CD4 cells is inversely associated with HIV-1 viremia, indicating that coinfection with HIV-1 may impair the MTB-specific cellular immune response such that, ultimately, these cells are less capable of containing MTB replication on reactivation, possibly contributing to an accelerated course of disease. Further studies regarding the impact of HIV-1 coinfection on the functional capacity of MTB-specific T cells in persons who do and do not develop active TB are required to identify potential mechanisms contributing to impairment of MTBspecific responses in individuals with chronic HIV-1 infection. References 1. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359: Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997; 119: Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey- Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. AIDS 1997; 11(Suppl B):S Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178: Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: Jouanguy E, Altare F, Lamhamedi S, et al. Interferon- receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 1996; 335: Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IF- NGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999; 21: Geluk A, van Meijgaarden KE, Franken KL, et al. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201 restricted CD8 T cells in HLA-transgenic mice and humans. J Immunol 2000; 165: Smith SM, Brookes R, Klein MR, et al. Human CD8 CTL specific for the mycobacterial major secreted antigen 85A. J Immunol 2000; 165: Lalvani A, Brookes R, Wilkinson RJ, et al. Human cytolytic and interferon -secreting CD8 T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998; 95: Valle MT, Megiovanni AM, Merlo A, et al. Epitope focus, clonal composition and Th1 phenotype of the human CD4 response to the secretory mycobacterial antigen Ag85. Clin Exp Immunol 2001; 123: Pathan AA, Wilkinson KA, Klenerman P, et al. Direct ex vivo analysis of antigen-specific IFN- -secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001; 167: Pathan AA, Wilkinson KA, Wilkinson RJ, et al. High frequencies of circulating IFN- -secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosisinfected subjects without disease. Eur J Immunol 2000; 30: Ravn P, Demissie A, Eguale T, et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 1999; 179: Pai M, Riley LW, Colford JM Jr. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16: Dheda K, Lalvani A, Miller RF, et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005; 19: Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001; 183: Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon- release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: Lawn SD, Bangani N, Vogt M, et al. Utility of interferon- ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa. BMC Infect Dis 2007; 7: Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004; 364: Scarpellini P, Tasca S, Galli L, Beretta A, Lazzarin A, Fortis C. Selected pool of peptides from ESAT-6 and CFP-10 proteins for detection of Mycobacterium tuberculosis infection. J Clin Microbiol 2004; 42: Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994; 94: Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77: Hervas-Stubbs S, Majlessi L, Simsova M, et al. High frequency of CD4 T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun 2006; 74: Skjot RL, Oettinger T, Rosenkrands I, et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 2000; 68: Shams H, Klucar P, Weis SE, et al. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4 and CD8 T cells in the context of multiple HLA alleles. J Immunol 2004; 173: Ulrichs T, Munk ME, Mollenkopf H, et al. Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol 1998; 28: JID 2008:197 (1 April) Day et al.
10 34. Delgado JC, Baena A, Thim S, Goldfeld AE. Aspartic acid homozygosity at codon 57 of HLA-DQ is associated with susceptibility to pulmonary tuberculosis in Cambodia. J Immunol 2006; 176: Mustafa AS, Shaban FA, Al-Attiyah R, et al. Human Th1 cell lines recognize the Mycobacterium tuberculosis ESAT-6 antigen and its peptides in association with frequently expressed HLA class II molecules. Scand J Immunol 2003; 57: Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81: Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007; 13: Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005; 174: Millington KA, Innes JA, Hackforth S, et al. Dynamic relationship between IFN- and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 2007; 178: Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: Day CL, Walker BD. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 2003; 198: Sutherland R, Yang H, Scriba TJ, et al. Impaired IFN- -secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006; 20: Amyes E, McMichael AJ, Callan MF. Human CD4 T cells are predominantly distributed among six phenotypically and functionally distinct subsets. J Immunol 2005; 175: Appay V, Dunbar PR, Callan M, et al. Memory CD8 T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8: Yue FY, Kovacs CM, Dimayuga RC, Parks P, Ostrowski MA. HIV-1- specific memory CD4 T cells are phenotypically less mature than cytomegalovirus-specific memory CD4 T cells. J Immunol 2004; 172: Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410: Lucas M, Day CL, Wyer JR, et al. Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J Virol 2004; 78: Kamath A, Woodworth JS, Behar SM. Antigen-specific CD8 T cells and the development of central memory during Mycobacterium tuberculosis infection. J Immunol 2006; 177: Junqueira-Kipnis AP, Turner J, Gonzalez-Juarrero M, Turner OC, Orme IM. Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis. Infect Immun 2004; 72: MTB-Specific T Cells in HIV-1 Infection JID 2008:197 (1 April) 999
Update on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town 1 Robert Koch s Therapeutic TB vaccine 1890: Purified Tuberculin Protein 1891: First negative reports
More informationExpansion of pre-existing, lymph node-localized CD8 + T cells during supervised treatment interruptions in chronic HIV-1 infection
Expansion of pre-existing, lymph node-localized CD8 + T cells during supervised treatment interruptions in chronic HIV-1 infection Marcus Altfeld, 1 Jan van Lunzen, 2 Nicole Frahm, 1,2 Xu G. Yu, 1 Claus
More informationHeterosubtypic immunity. Professor Ajit Lalvani FMedSci Chair of Infectious Diseases 14/07/2014
Protective cellular immune correlates against pandemic influenza: implications for universal vaccines 2 nd WHO Meeting on development and clinical trials of broadly protective influenza vaccines 5th 7th
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationSupplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads
Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads Representative example of comparative ex vivo tetramer enrichment performed in three independent experiments with either conventional
More informationPerformance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children
616 TUBERCULOSIS Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children T G Connell*, N Curtis*, S C Ranganathan, J P Buttery...
More informationPrinciple of the FluoroSpot assay. Anti-tag mab-green. Streptavidin-Red. Detection mab-tag. Detection mab-biotin. Analyte. Analyte.
FluoroSpot 1 The principle objective of the FluoroSpot assay is the simultaneous measurement of dual cytokine secretion at the single cell level. This is accomplished by using a mixture of monoclonal antibodies
More informationReceived 28 October 2005/Returned for modification 15 December 2005/Accepted 17 March 2006
JOURNAL OF CLINICAL MICROBIOLOGY, June 2006, p. 1944 1950 Vol. 44, No. 6 0095-1137/06/$08.00 0 doi:10.1128/jcm.02265-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. An In-House
More informationORIGINAL ARTICLE /j x. and 3 Department of Internal Medicine, University of Tor Vergata, Rome, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01391.x Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study D. Goletti 1,2, S. Carrara
More informationA Dual Color ELISPOT Assay
A Dual Color ELISPOT Assay Nicole Bernard, Ph.D., Salix Boulet and Michel Lubaki Ndongala, Research Institute of the McGill University Health Center The ELISPOT assay is considered by many to be a gold
More information2017 Vol. 23 No. 2 PP ISSN (Print)
43 FLORA AND FAUNA ISSN 2456-9364 (Online) 2017 Vol. 23 No. 2 PP 432-438 ISSN 0971-6920 (Print) LONGITUDINAL STUDY OF CD4 AND CD8 T CELLS PRODUCING CYTOKINE DURING DOTS THERAPY IN TB PATIENTS AND HEALTHY
More informationORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationIdentification of Mycobacterium tuberculosis-specific genomic regions encoding antigens inducing protective cellular immune responses
Indian Journal of Experimental Biology Vol. 47, June 2009, pp. 498-504 Identification of Mycobacterium tuberculosis-specific genomic regions encoding antigens inducing protective cellular immune responses
More informationstaining and flow cytometry
Detection of influenza virus-specific T cell responses by intracellular by cytokine intracellular staining cytokine staining and flow cytometry Detection of influenza virus-specific T cell responses and
More informationRecruitment of Mycobacterium tuberculosis specific CD4 + T cells to the site of infection for diagnosis of active tuberculosis
Original Article doi: 10.1111/j.1365-2796.2008.02012.x Recruitment of Mycobacterium tuberculosis specific CD4 + T cells to the site of infection for diagnosis of active tuberculosis J. Nemeth 1,2, H.-M.
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationCommercially available HLA Class II tetramers (Beckman Coulter) conjugated to
Class II tetramer staining Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to PE were combined with dominant HIV epitopes (DRB1*0101-DRFYKTLRAEQASQEV, DRB1*0301- PEKEVLVWKFDSRLAFHH,
More informationHuman Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4
Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4 Ankita Garg, Rodney Trout and Stephen A. Spector,,* Department
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More information[DOI] /j.issn
56 2018 1 1431 - [ ]- - T- SPOT.TB 5638 18T-SPOT.TB T-SPOT.TB86.5%(95%CI 71.2%~95.5%) 100%(95%CI 90.5%~100%) 52.9%(95%CI 27.8%~77.0%) 35.3%(95%CI 14.2%~61.7%) 80.0%(95%CI 64.4%~90.9%) 77.1%(95%CI 62.7%~88.0%)
More informationComparison of an In-house and a Commercial RD1-based ELISPOT-IFN-γ Assay for the Diagnosis of Mycobacterium tuberculosis Infection
Original Research Clinical Medicine & Research Volume 4, Number 4:266-272 2006 Marshfield Clinic http://www.clinmedres.org Comparison of an In-house and a Commercial RD1-based ELISPOT-IFN-γ Assay for the
More informationClinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
Eur Respir J 2007; 30: 945 950 DOI: 10.1183/09031936.00040007 CopyrightßERS Journals Ltd 2007 Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase,
More informationViral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment
JOURNAL OF VIROLOGY, Apr. 2003, p. 4911 4927 Vol. 77, No. 8 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.8.4911 4927.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Viral Persistence
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Portevin D, Moukambi F, Clowes P, et
More informationSupplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific
SUPPLEMENTARY FIGURE LEGEND Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific CD4 + T cells correlates with intracellular CTLA-4 levels. (a) Comparative CTLA-4 levels
More informationHIV acute infections and elite controllers- what can we learn?
HIV acute infections and elite controllers- what can we learn? Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) and HIV Pathogenesis Programme (HPP), Doris Duke
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationHelminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza
Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii Ringworm fungus HIV Influenza Candida Staph aureus Mycobacterium tuberculosis Listeria Salmonella Streptococcus Levels
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationMonitoring tuberculosis progression using MRI and stereology
Monitoring tuberculosis progression using MRI and stereology TB the problem Estimated number of new cases in 2007 2 million deaths; 9 million new cases p.a. TB kills someone every 15 secs, 9,153 cases
More informationLow Avidity CMV + T Cells accumulate in Old Humans
Supplementary Figure Legends Supplementary Figure 1. CD45RA expressing CMVpp65-specific T cell populations accumulate within HLA-A*0201 and HLA-B*0701 individuals Pooled data showing the size of the NLV/HLA-A*0201-specific
More informationx Lymphocyte count /µl CD8+ count/µl 800 Calculated
% Lymphocyte in CBC A. 50 40 30 20 10 Lymphocyte count /µl B. x10 3 2.5 1.5 C. 50 D. 1000 % CD3+CD8+ Cells 40 30 20 Calculated CD8+ count/µl 800 600 400 200 10 0 #61 #63 #64 #65 #68 #71 #72 #75 Figure
More informationTherapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
More informationDiagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis
Clin. Lab. 2014;60:1865-1870 Copyright ORIGINAL ARTICLE Diagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis XUEQIONG WU 1, *, YUANZHENG MA 2, *, LAN WANG 1, DAWEI LI 2, YOURONG YANG 1,
More informationX.-J. MA, X.-F. CHEN, W.-L. CHEN, R. CHEN, J. HUANG, X.-D. LUO, J.-Y. LIAO, X.-P. CHEN. Introduction. Patients and Methods
European Review for Medical and Pharmacological Sciences 2017; 21: 4675-4679 Study on the distribution of CD8 + memory T cell subsets and IFN-γ level during the spontaneous clearance of hepatitis B virus
More informationHIV-1 specific CD4 + T lymphocyte turnover and activation increase upon viral rebound
Research article HIV-1 specific CD4 + T lymphocyte turnover and activation increase upon viral rebound Thomas J. Scriba, 1 Hua-Tang Zhang, 1 Helen L. Brown, 1 Annette Oxenius, 2 Norbert Tamm, 3 Sarah Fidler,
More informationReview. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Interferon- assays for tuberculosis diagnosis
Interferon- assays for tuberculosis diagnosis Review Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review Madhukar Pai, Lee W Riley, and John M Colford Jr A major challenge in
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationEvaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay
In the name of God Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay presented by: M. Taheri Symptoms of TB Cough for more than two week Bloody
More informationª 2005 Lippincott Williams & Wilkins Curr Opin Pulm Med 11: ª 2005 Lippincott Williams & Wilkins.
Utility of the antigen-specific interferon-g assay for the management of tuberculosis Keertan Dheda a,b, Zarir F. Udwadia c, Jim F. Huggett a, Margaret A. Johnson b and Graham A.W. Rook a Purpose of review
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationSupplementary Figure 1. Example of gating strategy
Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte
More informationPotential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion
Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationThe CAPRI-T was one of two (along with the CAPRI-NK, see reference. [29]) basic immunological studies nested within the CAMELIA trial.
1 SUPPLEMENTARY INFORMATION Patient description and recruitment The CAPRI-T was one of two (along with the CAPRI-NK, see reference [29]) basic immunological studies nested within the CAMELIA trial. Patients
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationDetailed step-by-step operating procedures for NK cell and CTL degranulation assays
Supplemental methods Detailed step-by-step operating procedures for NK cell and CTL degranulation assays Materials PBMC isolated from patients, relatives and healthy donors as control K562 cells (ATCC,
More informationl e t t e r S Dominant TNF-α + Mycobacterium tuberculosis specific CD4 + T cell responses discriminate between latent infection and active disease
l e t t e r S Dominant Mycobacterium tuberculosis specific CD4 T cell responses discriminate between latent and active Alexandre Harari 1,2, Virginie Rozot 1, Felicitas Bellutti Enders 1, Matthieu Perreau
More informationMAIT cell function is modulated by PD-1 signaling in patients with active
MAIT cell function is modulated by PD-1 signaling in patients with active tuberculosis Jing Jiang, M.D., Xinjing Wang, M.D., Hongjuan An, M.Sc., Bingfen Yang, Ph.D., Zhihong Cao, M.Sc., Yanhua Liu, Ph.D.,
More informationDiagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs)
Diagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs) Educational aims To provide an overview of interferon- release assays (IGRAs) used for detection of tuberculosis
More informationTitle: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study
Author's response to reviews Title: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study Authors: Delia Goletti (d.goletti@tiscali.it)
More informationHD1 (FLU) HD2 (EBV) HD2 (FLU)
ramer staining + anti-pe beads ramer staining a HD1 (FLU) HD2 (EBV) HD2 (FLU).73.11.56.46.24 1.12 b CD127 + c CD127 + d CD127 - e CD127 - PD1 - PD1 + PD1 + PD1-1 1 1 1 %CD127 + PD1-8 6 4 2 + anti-pe %CD127
More informationExploring S. Typhi-Specific HLA-E Restricted Immune Responses in Pediatric and Adult Ty21a Recipients
Exploring S. Typhi-Specific HLA-E Restricted Immune Responses in Pediatric and Adult Ty21a Recipients Mark Rudolph PhD Candidate- University of Maryland Graduate Program in Life Sciences Institute for
More informationRapid antigen-specific T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154+CD4+ T cell Rapid antigen-specific T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central role
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationT Memory Stem Cells: A Long-term Reservoir for HIV-1
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 T Memory Stem Cells: A Long-term Reservoir for HIV-1 Maria J Buzon, PhD Ragon Institute of MGH, MIT and Harvard, Massachussetts General Hospital,
More informationDirect ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central
More informationAbu S. Mustafa,* Raja a Al-Attiyah, Sumaila N. M. Hanif, and Fatema A. Shaban
CLINICAL AND VACCINE IMMUNOLOGY, June 2008, p. 916 924 Vol. 15, No. 6 1556-6811/08/$08.00 0 doi:10.1128/cvi.00056-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Efficient Testing
More informationMore significance of TB- IGRA except for the diagnose of tuberculosis
Received: 16 August 2016 Accepted: 20 January 2017 DOI: 10.1002/jcla.22183 RESEARCH ARTICLE More significance of TB- IGRA except for the diagnose of tuberculosis Jun-Chi Xu 1,2 Ze-Yi Li 1 Xin-Nian Chen
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationImmune function in patients with HIV infection is
Reconstitution of Immune Responses to Tuberculosis in Patients With HIV Infection Who Receive Antiretroviral Therapy* Neil W. Schluger, MD, FCCP; Daniel Perez, MD; and Yuk Ming Liu, MPH Study objectives:
More informationNaive, memory and regulatory T lymphocytes populations analysis
Naive, memory and regulatory T lymphocytes populations analysis Jaen Olivier, PhD ojaen@beckmancoulter.com Cellular Analysis application specialist Beckman Coulter France Introduction Flow cytometric analysis
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationReceived 13 December 2004/Returned for modification 18 January 2005/Accepted 24 January 2005
JOURNAL OF CLINICAL MICROBIOLOGY, May 2005, p. 2070 2074 Vol. 43, No. 5 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.5.2070 2074.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationDecreased EBNA-1-specific CD8 T cells in patients with Epstein Barr virus-associated
Decreased EBNA-1-specific CD8 T cells in patients with Epstein Barr virus-associated nasopharyngeal carcinoma Mark H. Fogg a, Lori J. Wirth b, Marshall Posner b, and Fred Wang a,1 a Department of Medicine,
More informationQualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationThe World Health Organization s strategy. Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts
Eur Respir J 21; 36: 594 6 DOI: 1.1183/931936.17159 CopyrightßERS 21 Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts T. Oni*,#, J. Patel ", H.P. Gideon*, R. Seldon*,
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationDeveloping Understanding of CMI. Dr Tom Wilkinson Associate Professor of Respiratory Medicine Faculty of Medicine University of Southampton UK
Pre-existing influenza-specific CD4+ T cells correlate with homologous and heterotypic response and disease protection against influenza challenge in humans Do At Risk Groups Rely more on CMI to Viruses?
More informationClinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*
CHEST Clinical Utility of the QuantiFERON -2G Test for Elderly Patients With Active Tuberculosis* Yoshihiro Kobashi, MD, PhD; Keiji Mouri, MD; Shinich Yagi, MD; Yasushi Obase, MD, PhD; Naoyuki Miyashita,
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTuberculosis (TB) is an important global health problem. A
Monitoring of Peptide-Specific and Gamma Interferon-Productive T Cells in Patients with Active and Convalescent Tuberculosis Using an Enzyme-Linked Immunosorbent Spot Assay Fang-Fang Yang, a Zhi-Quan Tu,
More informationRecombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope
JOURNAL OF VIROLOGY, Apr. 2002, p. 3329 3337 Vol. 76, No. 7 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.7.3329 3337.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Recombinant
More informationProgressive Telomere Shortening of Epstein-Barr Virus Specific Memory T Cells during HIV Infection: Contributor to Exhaustion?
BRIEF REPORT Progressive Telomere Shortening of Epstein-Barr Virus Specific Memory T Cells during HIV Infection: Contributor to Exhaustion? Debbie van Baarle, 1 Nening M. Nanlohy, 1 Sigrid Otto, 1 Fiona
More informationSupporting Online Material for
www.sciencemag.org/cgi/content/full/1175194/dc1 Supporting Online Material for A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection John S. Yi, Ming Du, Allan J. Zajac* *To whom
More informationRelationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection
Eur Respir J 2010; 35: 619 626 DOI: 10.1183/09031936.00045509 CopyrightßERS Journals Ltd 2010 Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection
More informationDan Qiao, 1 Li Li, 1 Jian Guo, 2 Suihua Lao, 3 Xianlan Zhang, 3 Jianping Zhang, 4 and Changyou Wu 1 * on July 7, 2018 by guest
INFECTION AND IMMUNITY, Aug. 2011, p. 3358 3365 Vol. 79, No. 8 0019-9567/11/$12.00 doi:10.1128/iai.00014-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Mycobacterium tuberculosis
More informationIMMUNOLOGICAL MEMORY. CD4 T Follicular Helper Cells. Memory CD8 T Cell Differentiation
IMMUNOLOGICAL MEMORY CD4 T Follicular Helper Cells Memory CD8 T Cell Differentiation CD4 T Cell Differentiation Bcl-6 T-bet GATA-3 ROR t Foxp3 CD4 T follicular helper (Tfh) cells FUNCTION Provide essential
More informationEffect of tuberculin skin testing on a Mycobacterium tuberculosisspecific
ERJ Express. Published on January 10, 2007 as doi: 10.1183/09031936.00117506 Effect of tuberculin skin testing on a Mycobacterium tuberculosisspecific IFN-γ assay Eliane M.S. Leyten 1, Corine Prins 1,
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationSuperior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design
Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design Pratima Kunwar 1,7, Natalie Hawkins 2, Warren L. Dinges 1,3, Yi Liu 5, Erin E. Gabriel
More informationTherapeutic vaccines for HCV Chasing a Moving Target
Therapeutic vaccines for HCV Chasing a Moving Target Ellie Barnes (Fondation Merieux-Annecy March 213) Do we need a vaccine for HCV? HCV infects 17 million people worldwide Leading cause of end-stage
More informationHuman Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells
Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells Gavin M. Mason, Sarah Jackson, Georgina Okecha, Emma Poole, J. G. Patrick Sissons, John Sinclair,
More informationReceived 19 September 2007/Accepted 21 November 2007
JOURNAL OF VIROLOGY, Feb. 2008, p. 1723 1738 Vol. 82, No. 4 0022-538X/08/$08.00 0 doi:10.1128/jvi.02084-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Patterns of CD8 Immunodominance
More informationProfessor Ajit Lalvani
Diagnosing TB in the 21 st Century: New Tools to Tackle an Old Enemy Professor Ajit Lalvani, Department of Respiratory Medicine, National Heart and Lung Institute, Faculty of Medicine, St Mary s s Campus,
More informationBlocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationInhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers
JOURNAL OF VIROLOGY, Sept. 2011, p. 9646 9650 Vol. 85, No. 18 0022-538X/11/$12.00 doi:10.1128/jvi.05327-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Inhibition of HIV-1 Integration
More informationChapter 6. Discrepancy between Mycobacterium tuberculosis-specific interferon-γ release assays using short versus prolonged in vitro incubation
Discrepancy between Mycobacterium tuberculosis-specific interferon-γ release assays using short versus prolonged in vitro incubation Eliane M.S. Leyten 1,#, Sandra M Arend 1, Corine Prins 1, Frank G. J.
More informationDiagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients
CLINICAL RESEARCH STUDY Diagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients Sung-Han Kim, MD, a,b,c Kyoung-Ho Song, MD, a Su-Jin Choi, MS, b Hong-Bin
More informationReceived 15 August 2003/Returned for modification 6 November 2003/Accepted 26 January 2004
INFECTION AND IMMUNITY, May 2004, p. 2574 2581 Vol. 72, No. 5 0019-9567/04/$08.00 0 DOI: 10.1128/IAI.72.5.2574 2581.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Evaluation
More informationThe use of the tuberculin skin test (TST) to diagnose
Annals of Internal Medicine Article Prognostic Value of a T-Cell Based, Interferon- Biomarker in Children with Tuberculosis Contact Mustafa Bakir, MD; Kerry A. Millington, DPhil; Ahmet Soysal, MD; Jonathan
More informationLa risposta immune all infezione da virus ebola. Chiara Agrati, PhD
La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response
More informationEx vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*
Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* 1 Department of Laboratory Medicine - Laboratory of Hematology, Radboud University
More information